MedTrace Logo

Onset of Effect of Mometasone Nasal Spray in Induced Allergic Rhinitis (Study P03431)

NCT00783237 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 340

Last updated 2024-08-15

No results posted yet for this study

Summary

This was a single-dose study to determine the time it takes for mometasone furoate nasal spray to go in effect, after a single dose of 2 sprays per nostril. Patients who are eligible were exposed to ragweed pollen for 3 hours on one or two occasions. Patients who experienced adequate symptoms during the pollen exposure phase came back for a Treatment Phase visit. During the Treatment Phase visit, patients were exposed to ragweed pollen for 2 hours and then received either mometasone or placebo nasal spray. Symptom evaluations began on the patients every hour for the next 11 hours.

Conditions

  • Allergic Rhinitis

Interventions

DRUG

Mometasone

Mometasone Furoate Nasal Spray, single dose of 200 mcg (2 sprays per nostril)

DRUG

Placebo

Placebo nasal spray, single dose of 2 sprays per nostril

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-01
Primary Completion
2004-02-21
Completion
2004-02-21

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00783237 on ClinicalTrials.gov